Jazz Pharma's Vyxeos secures NICE recommendation in acute myeloid leukaemia
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for solution for infusion be adopted by the NHS for regular use, bringing the first new chemotherapy drug for the treatment of two types of secondary acute myeloid leukaemia (AML) in 40 years.
Specifically, the product has will now be used routinely by the NHS in newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two conditions with poor prognosis and the poorest survival rates of all AML subgroups. These conditions see around 680 cases per year, and account for around 25% of all AML incidence in the UK.
A liposomal formulation that works by delivering a synergistic molar ratio of daunorubicin and cytarabine, Vyxeos demonstrated a “significant” overall survival benefit for patients compared to current standard of care in Phase 3 trials.
"A diagnosis of acute myeloid leukaemia can have a huge emotional impact on the lives of patients, as well as their family and friends," commented Zack Pemberton-Whiteley, Patient Advocacy Director at Leukaemia Care. "We welcome the decision to recommend this treatment for adults with high-risk AML. Leukaemia Care has been working with NICE to enable patients to access this important new medicine, where options have been previously limited."
Iain McGill, Jazz Pharmaceuticals’ Senior Vice President, Europe and Rest of World, also remarked: "Jazz is delighted that Vyxeos will now be made routinely available on the NHS in England and Wales as people with therapy-related AML or AML with myelodysplasia-related changes have had limited treatment options until now. We believe that it is a meaningful medicine for patients with this rapidly progressing and life-threatening blood cancer."